Marharyta Semenikhina, Mykhailo Fedoriuk, Mariia Stefanenko, Christine A Klemens, Alena Cherezova, Brendan Marshall, Gentzon Hall, Vladislav Levchenko, Asish Kumar Solanki, Joshua H Lipschutz, Daria V Ilatovskaya, Alexander Staruschenko, Oleg Palygin
Angiotensin Receptor blockers (ARBs) are the first-line treatment for hypertension; they act by inhibiting signaling through the angiotensin 1 receptor (AT1R). Recently, a novel biased AT1R agonist, TRV120027 (TRV), that selectively activates the β-arrestin cascade and blocks the G-protein-coupled receptor pathway has been proposed as a potential blood pressure medication. Here, we explored the effects of TRV and associated β-arrestin signaling in podocytes, essential cells of the kidney filter...
December 5, 2023: Clinical Science (1979-)